Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment

Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin

Clin Mol Hepatol. 2024;30(3):388-405. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2023.0563

View: 2433 Download: 89 Crossref: 2

Review

Acute-on-chronic liver failure: Terminology, mechanisms and management

Vinay Kumar BR, Shiv Kumar Sarin

Clin Mol Hepatol. 2023;29(3):670-689. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0103

View: 6734 Download: 753 Web of Science: 15 Crossref: 18

Original Article

Alcohol associated liver cirrhotics have higher mortality after index hospitalization: Long-term data of 5,138 patients

Priyanka Jain, Saggere Muralikrishna Shasthry, Ashok Kumar Choudhury, Rakhi Maiwall, Guresh Kumar, Ankit Bharadwaj, Vinod Arora, Rajan Vijayaraghavan, Ankur Jindal, Manoj Kumar Sharma, Vikram Bhatia, Shiv Kumar Sarin

Clin Mol Hepatol. 2021;27(1):175-185. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0068

View: 5712 Download: 135 Web of Science: 14 Crossref: 14

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Shiv Kumar Sarin, Shvetank Sharma

Clin Mol Hepatol. 2020;26(4):639-651. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0196

View: 9205 Download: 259 Web of Science: 11 Crossref: 12

Original Article

Effects of zolpidem on sleep parameters in patients with cirrhosis and sleep disturbances: A randomized, placebo-controlled trial

Manoj Kumar Sharma, Sumeet Kainth, Sachin Kumar, Ankit Bhardwaj, Hemant Kumar Agarwal, Rakhi Maiwall, Kapil Dev Jamwal, Saggere Muralikrishna Shasthry, Ankur Jindal, Ashok Choudhary, Lovkesh Anand, Rajender Mal Dhamija, Guresh Kumar, Barjesh Chander Sharma, Shiv Kumar Sarin

Clin Mol Hepatol. 2019;25(2):199-209. Published online March 11, 2019

DOI: https://doi.org/10.3350/cmh.2018.0084

View: 15211 Download: 278 Web of Science: 23 Crossref: 22

1 |

Viewed By 5163	MAFLD: How is it different from NAFLD?
Viewed By 4908	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4601	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4574	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search